Johnson & Johnson (JNJ)vsMeta Platforms Inc. (META)
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
META
Meta Platforms Inc.
$609.63
-1.16%
COMMUNICATION SERVICES · Cap: $1.57T
Smart Verdict
WallStSmart Research — data-driven comparison
Meta Platforms Inc. generates 123% more annual revenue ($214.96B vs $96.36B). META leads profitability with a 32.8% profit margin vs 21.8%. META appears more attractively valued with a PEG of 0.93. META earns a higher WallStSmart Score of 83/100 (A-).
JNJ
Buy59
out of 100
Grade: C
META
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$160.99
Current Price
$221.32
$60.33 premium
Margin of Safety
+33.9%
Fair Value
$933.07
Current Price
$609.63
$323.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 33 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 40.6%
Revenue surging 33.1% year-over-year
Earnings expanding 62.4% YoY
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : META
The strongest argument for META centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 32.8% and operating margin at 40.6%. Revenue growth of 33.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : META
The primary concerns for META are Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while META is a growth play — different risk/reward profiles.
META carries more volatility with a beta of 1.24 — expect wider price swings.
META is growing revenue faster at 33.1% — sustainability is the question.
META generates stronger free cash flow (13.2B), providing more financial flexibility.
Bottom Line
META scores higher overall (83/100 vs 59/100), backed by strong 32.8% margins and 33.1% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Meta Platforms Inc.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?